Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bulevirtide in renal impairment
NCT05760300Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of bulevirtide in chronic hepatitis D (4 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State at 6 days and Maximum Observed Plasma Concentration at Steady State at 6 days. Started Mar 2023; status: completed.
02
Drugs
bulevirtide
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT05760300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05760300.